ARA-290

ARA-290

ARA-290 is a synthetic peptide derived from the erythropoietin (EPO) molecule, specifically designed to retain the tissue-protective properties of EPO without its erythropoietic effects. It is primarily investigated for its potential therapeutic benefits in treating chronic inflammatory and neuropathic conditions.

Structure and Mechanism of Action

ARA-290 is a small peptide that mimics the structure of the helix B surface peptide of erythropoietin. Unlike EPO, which binds to the erythropoietin receptor to stimulate red blood cell production, ARA-290 selectively interacts with the innate repair receptor (IRR), a heteromeric receptor complex formed by the β common receptor (CD131) and the erythropoietin receptor. This interaction triggers anti-inflammatory and tissue-protective signaling pathways without affecting erythropoiesis.

Therapeutic Applications

ARA-290 has been studied for its potential use in various medical conditions, including:

• Neuropathic Pain: ARA-290 has shown promise in reducing pain and improving nerve function in patients with small fiber neuropathy, a condition characterized by damage to small nerve fibers.

• Diabetes: In diabetic patients, ARA-290 may help alleviate symptoms of diabetic neuropathy and improve quality of life by reducing pain and inflammation.

• Inflammatory Diseases: Due to its anti-inflammatory properties, ARA-290 is being explored as a treatment for chronic inflammatory diseases, such as sarcoidosis and inflammatory bowel disease.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of ARA-290. These studies have generally shown that ARA-290 is well-tolerated and may provide symptomatic relief in conditions like small fiber neuropathy and sarcoidosis.

Safety and Side Effects

ARA-290 is generally well-tolerated, with a favorable safety profile. Common side effects reported in clinical trials include mild injection site reactions and transient headaches. Unlike erythropoietin, ARA-290 does not increase the risk of thromboembolic events or hypertension, as it does not stimulate red blood cell production.

Future Directions

Ongoing research aims to further elucidate the mechanisms of action of ARA-290 and expand its therapeutic applications. Future studies may explore its potential in other inflammatory and neurodegenerative diseases.

Also see

• Erythropoietin
• Neuropathic Pain
• Inflammation
• Diabetic Neuropathy

Resources

Latest articles - ARA-290

• Most recent articles
• Ongoing trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on ARA-290 for any updates.

‎